运动有益于患有晚期结直肠癌的患者 Exercise associated with benefit to patients with advanced colorectal cancer

中文版谷歌中文翻譯(90% 準確率) | English translation
Buy/Sell Your Domains Here。在這裡購買/出售您的域名
Contact Dr. Lu for information about cancer treatments。聯繫盧博士,獲取有關癌症治療資訊。
波士顿 – 根据一项新研究的结果,患有转移性结直肠癌的患者在接受化疗时进行中度运动,往往会延缓疾病进展,减少治疗后的严重副作用。

来自Dana-Farber癌症研究所和Brigham的研究人员表示,即使是低强度的运动,例如每周步行4小时或更长时间,也会使这项为期6年的研究中癌症进展或死亡减少近20%。妇女医院,在临床肿瘤学杂志上报道。该分析暗示报告更多身体活动的患者可能延长生存期,但数据无统计学意义。

“我们发现,从事某种类型体力活动的人在无进展生存期(PFS)方面有统计学上的显着改善,”该研究的资深作者Dana-Farber的医学博士,公共卫生硕士Jeffrey A. Meyerhardt说。 。 “虽然可能对整体存活率产生影响,但这在统计上并不显着 – 应该进一步研究。”

“在我们的研究中,身体活跃的患者似乎也能更好地耐受化疗,”该研究的第一作者Brendan Guercio说道,该研究是在他在Brigham and Women’s担任住院医师时进行的。 “相当于每日中度活动30分钟或更长时间的总体力活动与严重治疗相关毒性减少27%相关。”

以前的研究发现,定期运动可以降低疾病复发和死亡的风险,结肠癌尚未转移到身体的其他部位。研究人员表示,这是第一项研究晚期转移性结直肠癌的体力活动与生存相关性的研究。患者参加了由肿瘤临床试验联盟进行的由国家癌症研究所赞助的晚期结直肠癌化疗的3期研究。在开始治疗后一个月内,患者被邀请完成关于他们在过去两个月中的平均身体活动的问卷。最终参与人数包括1,218名患者。研究人员表示,虽然这些数据非常重要,但随机前瞻性试验的进一步研究将有助于验证结果。

根据患者的描述,研究人员根据代谢当量任务(MET) – 每周小时量化他们的身体活动量 – 这是运动研究中使用的标准量度。剧烈活动被定义为需要六个或更多MET的任何活动,例如跑步,骑自行车,网球,滑雪或膝部游泳。非活力的活动包括步行,爬楼梯或瑜伽。

对数据的分析显示PFS具有统计学上的显着差异 – 患者在癌症进展或患者死亡之前完成问卷后的时间长度。 PFS的差异几乎是20%,有利于那些锻炼更多的人。

Meyerhardt补充说,这些发现“有助于鼓励患者进行锻炼,并将患者转诊至物理治疗师或计划,如YMCA LIVESTRONG计划,该计划为癌症患者进行小组培训。”

该分析还发现,每周活动18小时或更多MET小时的患者的总生存率(任何原因引起的死亡)比每周活动少于3小时MET的患者提高15%。然而,这种差异在统计上并不显着,这意味着它可能是偶然的结果。

Comment:  All cancer patients should exercise intensely.
NEWS RELEASE 

Exercise associated with benefit to patients with advanced colorectal cancer

DANA-FARBER CANCER INSTITUTE

IMAGE
IMAGE: DR. MEYERHARDT IS THE CLINICAL DIRECTOR OF THE GASTROINTESTINAL CANCER CENTER AT DANA-FARBER CANCER INSTITUTE AND THE SENIOR AUTHOR OF THE STUDY. view more 

CREDIT: DANA-FARBER CANCER INSTITUTE

  • First study to examine the association of physical activity with patient survival in advanced, metastatic colorectal cancer
  • Even low-intensity exercise was associated with a reduction in progression free survival

BOSTON – Patients with metastatic colorectal cancer who engaged in moderate exercise while undergoing chemotherapy tended to have delayed progression of their disease and fewer severe side effects from treatment, according to the results of a new study.

Even low-intensity exercise, such as walking four or more hours a week, was associated with a nearly 20 percent reduction in cancer progression or death over the course of the six-year study, said researchers from Dana-Farber Cancer Institute and Brigham and Women’s Hospital, reporting in the Journal of Clinical Oncology. The analysis hinted at a possible lengthening of survival in patients who reported greater physical activity, but the data were not statistically significant.

“What we found was that people who engaged in some type of physical activity had a statistically significant improvement in progression-free survival (PFS),” said Jeffrey A. Meyerhardt, MD, MPH, of Dana-Farber, senior author of the study. “While there may also be an impact on overall survival, it was not statistically significant – and should be studied further.”

“Physically active patients in our study also appeared to tolerate chemotherapy better,” said Brendan Guercio, MD, first author of the study which was conducted while he was working as a hospitalist at Brigham and Women’s. “Total physical activity equivalent to 30 or more minutes of moderate daily activity was associated with a 27 percent reduction in severe treatment-related toxicities.”

Previous studies have found that regular exercise can reduce the risk of disease recurrence and death from colon cancer that has not metastasized to other parts of the body. Researchers say this is the first study to examine associations of physical activity with survival in advanced, metastatic colorectal cancer. Patients participated in a phase 3 study of chemotherapy for advanced colorectal cancer conducted by the Alliance for Clinical Trials in Oncology and sponsored by the National Cancer Institute. Within a month after beginning treatment, patients were invited to complete a questionnaire about their average physical activity over the previous two months. The final number of participants included 1,218 patients. While the data are significant, further research with a randomized prospective trial will help validate the results, the researchers said.

Based on the patients’ descriptions, researchers quantified their physical activity in terms of metabolic equivalent task (MET)-hours per week – a standard measure used in research studies of exercise. Vigorous activity was defined as any activity requiring six or more METs, such as running, biking, tennis, skiing, or lap swimming. Non-vigorous activities included walking, climbing stairs, or yoga.

Analysis of the data revealed a statistically significant difference in PFS – the length of time after the patient completed the questionnaire before the cancer progressed or the person died. The difference in PFS was almost 20 percent in favor of those who exercised more.

Meyerhardt added that the findings “help justify encouraging patients to exercise and referring patients to physical therapists or programs like the YMCA LIVESTRONG program that does small group training for patients with cancer.”

The analysis also found that patients who engaged in 18 or more MET-hours per week of activity had a 15 percent improvement in overall survival (death from any cause) than patients who engaged in less than three MET-hours per week of activity. However, that difference was not statistically significant, meaning it could have resulted from chance.

###

The study authors noted that all patients in the study were being treated with chemotherapy and the study results do not suggest that exercise should be substituted for chemotherapy or any other standard therapy.

Funding for this study was provided by: the National Institutes of Health under Award Numbers U10CA180821 (Alliance Chairman’s Grant to the Alliance for Clinical Trials in Oncology) and U10CA180882 (Alliance Statistics and Data Center Grant to the Alliance for Clinical Trials in Oncology), U10CA180791, U10CA180795, U10CA180826, U10CA180836, U10CA180838, U10CA180850, U10CA180867, UG1CA189858, UG1CA189869; U10CA180820 (ECOG-ACRIN); U10CA180888 and U10CA180830 (SWOG); R01CA149222, R01CA169141, R01CA118553, K07CA197077, R01CA205406, and CA180820; and the Stand-Up-to-Cancer Colorectal Dream Team Grant. Also supported in part by funds from Bristol-Myers Squibb, Genentech, Eli Lily and Company, Pfizer, and Sanofi. Meyerhardt is supported by the Douglas Gray Woodruff Chair in Colorectal Cancer Research Fund, the Guo Shu Shi Fund, Anonymous Family Fund for Innovations in Colorectal Cancer, and the George Stone Family Foundation.

About Dana-Farber

Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. It is the only center ranked in the top 4 of U.S. News and World Report’s Best Hospitals for both adult and pediatric cancer care.

Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. We provide the latest in cancer for adults through Dana-Farber/Brigham and Women’s Cancer Care and for children through Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world.

About the Alliance for Clinical Trials in Oncology

The Alliance for Clinical Trials in Oncology develops and conducts clinical trials with promising new cancer therapies and utilizes the best science to develop optimal treatment and prevention strategies for cancer, and research methods to alleviate side effects of cancer and cancer treatments. The Alliance is part of the National Clinical Trials Network (NCTN) sponsored by the National Cancer Institute (NCI) and serves as a research base for the NCI Community Research Oncology Program (NCORP). The Alliance comprises nearly 10,000 cancer specialists at hospitals, medical centers, and community clinics across the United States and Canada. To learn more about the Alliance, visit http://www.allianceforclinicaltrialsinoncology.org/.

$$$ If you are interested in a writer or editor position, check out here.We are hiring. $$$

38

No Responses

Write a response

eighteen + thirteen =